'New regulation limiting generic drugs will change industrial paradigm'

Korea Biomedical Review

27 July 2021 - The Korea Pharmaceutical and Bio-pharma Manufacturers Association said the revision of the Pharmaceutical Affairs Act to restrict generic drugs would be an inflection point to bring about a paradigm shift in the biopharmaceutical industry.

The KPBMA made these and other points in its latest policy report in the form of a forum, "Biopharmaceutical industry in a transformational period."

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder